4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT Voorraadrapport

Marktkapitalisatie: US$420.7m

4D Molecular Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

4D Molecular Therapeutics's earnings have been declining at an average annual rate of -22.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 6% per year.

Belangrijke informatie

-22.1%

Groei van de winst

29.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroei6.0%
Rendement op eigen vermogen-18.7%
Nettomarge-543.5%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29
We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Opbrengsten en kosten

Hoe 4D Molecular Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqGS:FDMT Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2420-110410
31 Mar 2420-105390
31 Dec 2321-101360
30 Sep 2322-96340
30 Jun 232-111330
31 Mar 232-110330
31 Dec 223-107330
30 Sep 222-105320
30 Jun 223-102320
31 Mar 2217-81310
31 Dec 2118-71280
30 Sep 2117-67280
30 Jun 2123-52230
31 Mar 2112-60190
31 Dec 2014-57170
30 Sep 2017-52160
30 Jun 2010-61160
31 Mar 208-54150
31 Dec 197-49140
30 Sep 199-35100
30 Jun 1913-2190
31 Mar 1914-1580
31 Dec 1814-1060
31 Dec 176-1130

Kwaliteitswinsten: FDMT is currently unprofitable.

Groeiende winstmarge: FDMT is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: FDMT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.

Versnelling van de groei: Unable to compare FDMT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: FDMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: FDMT has a negative Return on Equity (-18.68%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden